Blake Ronnebaum helps innovators protect and advance their ideas by guiding them through every stage of the patent process in the United States and abroad. With a background in Chemical Engineering, he applies his knowledge of materials science, biotechnology and industrial processes to help clients develop effective intellectual property strategies. He has represented clients across industries including pharmaceuticals, animal health, biotechnology and chemical processing, as well as in technology areas including batteries, hydrogen generation and medical devices.

Blake’s practice focuses on:

  • Preparing and prosecuting patent applications in the United States;
  • Leading patent prosecution strategy in non-U.S. countries, particularly in Europe, India, Japan, China, Korea, Australia, Brazil, United Arab Emirates, among others;
  • Conducting patentability and freedom-to-operate analyses;
  • Assisting with due diligence investigations, non-infringement investigations and invalidity investigations; and
  • Providing support for patent litigation and post-grant proceedings in the United States and Japan.

By combining technical knowledge with legal strategy, Blake partners with clients to develop tailored strategies that protect innovation and support business objectives.

Education

  • University of Kansas School of Law (J.D., 2020)
    • Kansas State University (B.S., 2017)
      • Chemical Engineering, magna cum laude

    Bar Admission

    • Admitted to practice before the United States Patent and Trademark Office, 2019
    • Missouri, 2020

    Professional Affiliations

    • National LGBTQ+ Bar Association, 2025
    • American Bar Association, 2019
      • Intellectual Property Law Section 
    • Kansas City Metropolitan Bar Association, 2020

    Recognition

    • Named one of Best Lawyers: Ones to Watch® in America in:
      • Intellectual Property Law, 2026
      • Patent Law, 2026
    Publications
    Polsinelli Life Sciences Spotlight - Volume 1 - Looking Back, Moving Forward: A Year in Life Sciences
    We are excited to present the first volume of our Life Sciences Spotlight report, where we explore the latest trends, innovations, and breakthroughs shaping the future of life sciences. This report offers a comprehensive view of the dynamic landscape, covering: Policy Opportunities in 2025 Washington Recent Life Sciences Deal Trends 2024 Sampling of Representative Life Sciences Deals Living in a Post-Chevron World – Loper Bright and the Impact on FDA-Regulated Industries Are Medical Device Disputes the Latest “Smartphone Wars” at the ITC? Q&A with SxanPro Polsinelli Client is Saving Your Bananas Proposed Changes to Terminal Disclaimer Practice in Patent Applications Withdrawn after Industry Backlash Artificial Intelligence and Machine Learning Patenting Pitfalls in the Life Sciences Industry Q&A with Portal Innovations A Busy Biotech Week Boston Perspectives from the Host of The 10 Minute HealthBizCast
    Read More
    USPTO Proposes Rule Adding Conditions of Enforceability to Patents Tied to Terminal Disclaimers
    On Friday, May 10, 2024, the USPTO issued a notice of proposed rulemaking in the Federal Register directed at amending the rules of practice to add a requirement for terminal disclaimers filed to overcome rejections for nonstatutory double patenting. In the summary of the rule, the USPTO notes that the proposed change would require terminal disclaimers filed to include an agreement by the disclaimant that any patent related to the terminal disclaimer (including the patent in which the terminal disclaimer is filed and any disclaimed patent) will be enforceable only if the patent is not tied and has never been tied directly or indirectly to a patent by one or more terminal disclaimers filed to obviate nonstatutory double patenting rejections
    Read More